Literature DB >> 32206696

Understanding of Zaire ebolavirus-human protein interaction for drug repurposing.

Mathavan Muthaiyan1, Shilpa Sri Pushan1, Leimarembi Devi Naorem1, Amouda Venkatesan1.   

Abstract

The Ebola virus is a human aggressive pathogen causes Ebola virus disease that threatens public health, for which there is no Food Drug Administration approved medication. Drug repurposing is an alternative method to find the novel indications of known drugs to treat the disease effectively at low cost. The present work focused on understanding the host-virus interaction as well as host virus drug interaction to identify the disease pathways and host-directed drug targets. Thus, existing direct physical Ebola-human protein-protein interaction (PPI) was collected from various publicly available databases and also literature through manual curation. Further, the functional and pathway enrichment analysis for the proteins were performed using database for annotation, visualization, and integrated discovery and the enriched gene ontology biological process terms includes chromatin assembly or disassembly, nucleosome organization, nucleosome assembly. Also, the enriched Kyoto Encyclopedia of Genes and Genome pathway terms includes systemic lupus erythematosus, alcoholism, and viral carcinogenesis. From the PPI network, important large histone clusters and tubulin were observed. Further, the host-virus and host-virus-drug interaction network has been generated and found that 182 drugs are associated with 45 host genes. The obtained drugs and their interacting targets could be considered for Ebola treatment. © Indian Virological Society 2020.

Entities:  

Keywords:  Drug repurposing; Host–virus interaction; Protein–protein interaction; Zaire Ebola virus

Year:  2020        PMID: 32206696      PMCID: PMC7085497          DOI: 10.1007/s13337-020-00570-6

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  46 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry.

Authors:  Derek Dube; Kathryn L Schornberg; Charles J Shoemaker; Sue E Delos; Tzanko S Stantchev; Kathleen A Clouse; Christopher C Broder; Judith M White
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-03       Impact factor: 11.205

3.  Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b.

Authors:  Ashwini Khanderao Jadhav; Sankunny Mohan Karuppayil
Journal:  In Silico Pharmacol       Date:  2017-06-30

4.  Association of ebola virus matrix protein VP40 with microtubules.

Authors:  Gordon Ruthel; Gretchen L Demmin; George Kallstrom; Melodi P Javid; Shirin S Badie; Amy B Will; Timothy Nelle; Rowena Schokman; Tam L Nguyen; John H Carra; Sina Bavari; M Javad Aman
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.

Authors:  Toshio Uesaka; Tadahisa Shono; Daisuke Kuga; Satoshi O Suzuki; Hiroaki Niiro; Kyoko Miyamoto; Kenichi Matsumoto; Masahiro Mizoguchi; Masaru Ohta; Toru Iwaki; Tomio Sasaki
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

6.  A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

Authors:  Sanjay Goel; Alain C Mita; Monica Mita; Eric K Rowinsky; Quincy S Chu; Nancy Wong; Christopher Desjardins; Fang Fang; Mendel Jansen; Dale E Shuster; Sridhar Mani; Chris H Takimoto
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

7.  Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.

Authors:  Jennifer Kouznetsova; Wei Sun; Carles Martínez-Romero; Gregory Tawa; Paul Shinn; Catherine Z Chen; Aaron Schimmer; Philip Sanderson; John C McKew; Wei Zheng; Adolfo García-Sastre
Journal:  Emerg Microbes Infect       Date:  2014-12-17       Impact factor: 7.163

8.  How Taxol/paclitaxel kills cancer cells.

Authors:  Beth A Weaver
Journal:  Mol Biol Cell       Date:  2014-09-15       Impact factor: 4.138

Review 9.  Discovering Drugs for the Treatment of Ebola Virus.

Authors:  Sandra L Bixler; Allen J Duplantier; Sina Bavari
Journal:  Curr Treat Options Infect Dis       Date:  2017-08-04

10.  Ebola virus secreted glycoprotein decreases the anti-viral immunity of macrophages in early inflammatory responses.

Authors:  Jillian H Bradley; Ametria Harrison; Ashley Corey; Nathan Gentry; Randal K Gregg
Journal:  Cell Immunol       Date:  2017-11-27       Impact factor: 4.868

View more
  1 in total

Review 1.  Drug targets for COVID-19 therapeutics: Ongoing global efforts.

Authors:  Ambrish Saxena
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.